Everolimus in combination with Exemestane in hormone receptor-positive, locally advanced or metastatic breast cancer patients progressing on prior non-steroidal aromatase inhibitors (NSAIs) : BALLET study (CRAD001YIC04)

Breast Cancer Patients Progressing on Prior Non-steroidal Aromatase Inhibitors (NSAIs): BALLET Study (CRAD001YIC04) Guy Jerusalem,1 Gabriella Mariani,2 Eva M Ciruelos Gil,3 Miguel Martin,4 Vivianne CG Tjan-Heijnen,5 Patrick Neven,6 Joaquin Gavila Gregori,7 Andrea Michelotti,8 Filippo Montemurro,9 Istvan Lang,10 Jozef Mardiak,11 Bjorn Naume,12 Maura Camozzi,13 Katia Lorizzo,13 Dariusz Brenski,13 Pierfranco Conte14 1Site du Sart Tilman, CHU de Liege, University of Liege, Liege, Belgium; 2Fondazione IRCCS – Istituto Nazionale dei Tumori, Milan, Italy; 3Hospital Universitario 12 de Octubre, Madrid, Spain; 4Hospital General Universitario Gregorio Maranon, Universidad Complutense, Madrid, Spain; 5Maastricht University Medical Centre, Maastricht, The Netherlands; 6Multidisciplinary Breast Centre, University Hospitals Leuven, Leuven, Belgium; 7Fundacion Instituto Valenciano de Oncologia, Valencia, Spain; 8Oncology Unit 1, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy; 9Fondazione del Piemonte per l’Oncologia, Istituto di Candiolo – IRCCS, Candiolo, Italy; 10National Institute of Oncology, Budapest, Hungary; 11National Cancer Institute, Bratislava, Slovak Republic; 12K.G. Jebsen Centre for Breast Cancer Research, Oslo University Hospital, Oslo, Norway; 13Novartis Farma S.p.A., Origgio, Italy; 14Istituto Oncologico Veneto – IRCCS and Universita di Padova, Padua, Italy